1. Home
  2. RGP vs BMEA Comparison

RGP vs BMEA Comparison

Compare RGP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resources Connection Inc.

RGP

Resources Connection Inc.

HOLD

Current Price

$4.71

Market Cap

138.0M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.16

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGP
BMEA
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
138.1M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
RGP
BMEA
Price
$4.71
$1.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$7.00
$9.83
AVG Volume (30 Days)
313.6K
1.1M
Earning Date
04-08-2026
05-12-2026
Dividend Yield
6.85%
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
$551,331,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.87
52 Week High
$6.07
$3.07

Technical Indicators

Market Signals
Indicator
RGP
BMEA
Relative Strength Index (RSI) 61.95 35.89
Support Level $4.21 $1.05
Resistance Level $4.82 $1.47
Average True Range (ATR) 0.22 0.10
MACD 0.01 -0.02
Stochastic Oscillator 89.92 15.79

Price Performance

Historical Comparison
RGP
BMEA

About RGP Resources Connection Inc.

Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: